|
07 Jun 2021 |
OliX Pharmaceuticals Subsidiary mCureX Announces Business Agreements to Advance Development of mRNA Vaccines and Therapeutics
|
|
06 Jun 2021 |
Samsung Pharm & GemVax present pancreatic cancer immunotherapeutic drug, RIAVAX™, phase III results at ASCO 2021
|
|
04 Jun 2021 |
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
|
|
04 Jun 2021 |
Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
|
|
04 Jun 2021 |
Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program
|
|
04 Jun 2021 |
Advaccine Announces First Participants Dosed in Phase 2 Study of ADV110 Evaluating Respiratory Syncytial Virus (RSV) Vaccine Candidate in Australia
|
|
02 Jun 2021 |
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
|
|
01 Jun 2021 |
Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine
|
|
27 May 2021 |
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
|
|
26 May 2021 |
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
|
|
26 May 2021 |
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
|
|
26 May 2021 |
Elixirgen Therapeutics Announces Dosing of First and Second Participants in its COVID-19 Vaccine Phase 1/2 Clinical Trial at Fujita Health University
|
|
26 May 2021 |
Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June
|
|
21 May 2021 |
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
|
|
20 May 2021 |
Ultimovacs’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data
|
|
20 May 2021 |
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
|
|
18 May 2021 |
Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
|
|
18 May 2021 |
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
|
|
17 May 2021 |
AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update
|
|
17 May 2021 |
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
|
|
12 May 2021 |
INOVIO’s Pan-COVID-19 vaccine candidate (INO-4802) induces broad immunity against major viral variants in preclinical studies
|
|
12 May 2021 |
Providence Therapeutics Announces Very Favorable Interim Phase 1 Trial Data for PTX-COVID19-B, its mRNA Vaccine Against COVID-19
|
|
11 May 2021 |
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
|
|
10 May 2021 |
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
|
|
08 May 2021 |
Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults
|
